AVITA's Q4 sales missed guidance due to hospitals deferring year end purchases. However, January's rebound suggests a strong ...

AVITA Medical (NASDAQ:RCEL – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...

Cohealyx adds $1.35 billion in TAM, PermeaDerm contributes $135 million in TAM and RECELL provides a potential of $1.5 billion in TAM. In the aggregate, AVITA Medical now has a combined $3.5 ...

We came across a bullish thesis on AVITA Medical, Inc. (RCEL) on Substack by Steve Wagner. In this article, we will summarize ...

AVITA Medical Inc (AVHHL) reported a 30% increase in commercial revenue for Q4 2024 compared to the same period in 2023, driven by the adoption of RECELL GO. The company successfully launched ...

AVITA Medical Inc (AVHHL) reported a 30% increase in commercial revenue for Q4 2024 compared to the same period in 2023, driven by the adoption of RECELL GO. The company successfully launched ...

One last point, Cohealyx can also be used independently of RECELL as demonstrated in the Wexner Medical Center case discussed earlier, resulting in an additional increase of the total addressable ...

D. Boral Capital lowered the firm’s price target on Avita Medical (RCEL) to $22 from $25 and keeps a Buy rating on the shares. The CFO of Avita ...

D. Boral Capital reaffirmed their buy rating on shares of AVITA Medical (NASDAQ:RCEL – Free Report) in a report issued on Friday,Benzinga reports. The firm currently has a $25.00 price objective on ...

Revenue: US$64.3m (up 28% from FY 2023). Net loss: US$61.8m (loss widened by 75% from FY 2023). US$2.39 loss per share (further deteriorated from US$1.40 loss in FY 2023). Revenue missed analyst ...

Commercialisation of the Company's regenerative product.